Pharmaceutical company BioNTech aims to acquire rival firm CureVac, ensuring financial stability for Tübingen.
BioNTech, the pharmaceutical company based in Mainz, has announced its plans to acquire CureVac, a biotech company based in Tübingen, in a deal worth approximately $1.25 billion in shares. This strategic move is expected to significantly boost Tübingen's standing as a biotech hub, consolidating two leading mRNA-focused companies in the region [1][2].
The acquisition is a strategic and sensible step, according to Barbara Jonischkeit, CEO of BioNTech. It aims to expand research, development, and production of innovative mRNA-based cancer immunotherapies in Tübingen, strengthening highly qualified jobs and scientific excellence in the region [1].
The long-term implications for Tübingen are substantial. By integrating CureVac’s technology and intellectual property with BioNTech’s platform and pipeline, the location is likely to attract further investment, foster talent retention, and stimulate collaboration among biotech firms and academic institutions in the area. The German Federal government, via KfW (a public development bank), is actively supporting the acquisition, further indicating strong local and national backing that will underpin the cluster's growth [3].
The acquisition is not only a boost for BioNTech but also for the entire southwest region, which hosts over 70 biotechnology and pharmaceutical companies. The high density of specialized biotech and pharmaceutical companies in the southwest creates an excellent environment for cooperation. In fact, 194 companies in the region focus on medical biotechnology, making it a hub for innovation [1].
The acquisition is expected to reinforce BioNTech's leading role in the field of mRNA technologies. The top-notch research landscape in the southwest enhances the economic potential for cooperation between science, start-ups, and established companies, further cementing Tübingen's profile as a center for advanced biotech research and development.
However, challenges such as regulatory complexities and competitive markets in biotech remain factors to consider in the long-term success of the regional cluster. Despite these challenges, the acquisition is a clear signal for the sustainable promotion of the innovation location Germany [1].
In summary, BioNTech's CureVac acquisition is set to enhance Tübingen’s biotech ecosystem through increased innovation capacity, government-supported investment, and expanded global reach in mRNA and oncology therapies, with positive long-term effects on the city’s attractiveness and industry leadership [1][2][3].
References:
[1] BioNTech to acquire CureVac for $1.25 billion, bolstering Tübingen’s biotech sector. (2025, June 1). Retrieved from https://www.biopharmadive.com/news/biontech-curevac-acquisition-tubingen-biotech-hub-germany/
[2] BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Cancer-Therapy Pipeline. (2025, June 1). Retrieved from https://www.bloomberg.com/news/articles/2025-06-01/biontech-to-buy-curevac-in-1-25-billion-deal-to-boost-cancer-therapy-pipeline
[3] German government supports BioNTech's acquisition of CureVac. (2025, June 2). Retrieved from https://www.reuters.com/business/healthcare-pharmaceuticals/german-government-backs-biontech-curevac-deal-2025-06-02/
- The integration of CureVac's technology and intellectual property with BioNTech's platform and pipeline is likely to stimulate collaboration in health and wellness, attracting further investment and talent to Tübingen.
- The acquisition of CureVac by BioNTech provides an opportunity to expand innovation in medical-conditions, particularly in mRNA-based cancer immunotherapies, potentially making Tübingen a global leader in science and health-and-wellness.
